VYEPTI permanent J-code (J3032) is now available. Learn more

Chronic migraine patient profile*

*Chronic migraine was defined as ≥15 to ≤26 headache days per month, of which ≥8 were migraine days.1 One month was defined as 28 consecutive days.2

Meet Anne, a fictitious patient with chronic migraine

For patients like Anne,
what factor would lead
you to consider switching
to a different preventive treatment?

Here’s how others responded:

Previous preventive medication failure

Emergency room IV rescue medication required within the last 6 months

Inability to attend/effectively engage at work

Increasing depression and anxiety over her uncontrolled migraines

Needs an infrequent treatment schedule due to busy work and travel schedule

Meet Anne, a fictitious patient with chronic migraine

Meet Anne†‡

†Fictitious patient case.

PATIENT INFORMATION

Age: 47 years old

Sex: Female

Diagnosis: Chronic migraine,12 years

Mean migraine days per month: 16

TREATMENT HISTORY

Migraine medication use

  • Has tried a beta blocker and a tricyclic antidepressant for migraine prevention
  • Additionally, treating migraine acutely with multiple prescription oral medications, including triptans

Concomitant medication use

  • Presently taking medications for generalized anxiety disorder, major depressive disorder, and insomnia 

FACTORS FOR CONSIDERATION

  • Discontinued previous preventive medications due to lack of response
  • Visited emergency room within the last 6 months due to migraine and was treated with IV acute medications
  • Frequent absenteeism from work; fears potential job loss
  • Is frustrated and is increasingly depressed and anxious over her uncontrolled migraine
  • Infrequent treatment schedule would be ideal based on her busy work and travel schedule 

‡This patient profile may represent some of the healthcare challenges that could be encountered during typical clinical practice. Symptoms and responses to any treatment may vary. As always, use your clinical judgement.

Consider VYEPTI for your patients like Anne

With one 30-minute IV infusion every 12 weeks, VYEPTI has the potential to help some patients overcome challenges associated with migraine.1

TALK TO YOUR PATIENTS ABOUT TREATMENT WITH VYEPTI

Learn more about VYEPTI in chronic migraine

CHRONIC MIGRAINE STUDY DESIGN
CHRONIC MIGRAINE STUDY RESULTS

You may also be interested in:

DOSING AND ADMINISTRATION
REGISTER FOR UPDATES
SAFETY DATA
IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

References:
  1. VYEPTI (eptinezumab-jjmr) [package insert]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.
  2. Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94(13):e1365-e1377. 

© 2021 Lundbeck. All rights reserved. VYEPTI, VYEPTI CONNECT, and VYEPTI GO are trademarks of Lundbeck Seattle BioPharmaceuticals, Inc. EPT-B-100032v4

This website is intended for US healthcare professionals only.

Site Map Terms of Use and Privacy Policy Contact Us